An antibody raised against huIgG, the constant region of human immunoglobulin heavy chains that play a role in antigen binding during the recognition phase of humoral immunity.
Catalogue number crb2005688 Antibody Anti-huIgG antibody Antigen Peptide KLH conjugated synthetic peptide crb1200897 Protein ID UniProtKB - P01857, P01861, P0DOX5 Aliases Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, Immunoglobulin gamma-1 heavy chain Cross-Reactivity Human Host Species Rabbit Antibody Type Polyclonal Concentration 0.5 mg/ml Glycine (R1G), 0.1 mg/mL TEA (R1T), 0.5 mg/mL Glycine (R2G), 0.2 mg/mL TEA (R2T) Target huIgG Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles. References
Chu et al., (2019). IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res. Int., 2019: 1. doi: 10.1155/2019/7201562.
Strohl et al., (2012). Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry. Therapeutic Antibody Engineering. Woodhead Publishing. Pages 197-595.
Thomson (2016). IgG Structure and Function. Encyclopedia of Immunobiology. Academic Press. Pages 15-22.
huIgG serves as a membrane-bound or secreted immunoglobulin receptor that stimulates differentiation and clonal expansion of B lymphocytes upon specific antigen binding to form immunoglobulin-secreting plasma cells. Immunoglobulins are important during the recognition phase of humoral immunity and are critical mediators of effector mechanisms through the binding of soluble and membrane protein antigens via the variable domain.
The abundance of the human IgG1 isotope makes it an attractive target for biopharmaceutical research, particularly in drug development and antibody therapeutics. Increased levels of IgG heavy chain have been observed in prostate cancer patients, with huIgG predicted to play a role in the regulation of prostate cancer growth through the MEK/ERK/c-Myc pathway.